Unknown PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT04025437

Neoadjuvant Radiotherapy for HCC Involving Type I PVTT

Neoadjuvant Radiotherapy for Patients With Hepatocellular Carcinoma Involving Type I Portal Vein Tumor Thrombus

Sponsor: Guangxi Medical University

Interventions Hepatectomy alone Neoadjuvant radiotherapy

Updated 6 times since 2019 Last updated: Sep 1, 2019 Started: Mar 1, 2019 Primary completion: Dec 30, 2021 Completion: Dec 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Hepatocellular Carcinoma, this trial is ongoing. The trial is conducted by Guangxi Medical University and has accumulated 6 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2/PHASE3

Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2022 — Jul 2024 [monthly]

Unknown Status PHASE2_PHASE3

Status: Active Not Recruiting → Unknown Status
Jan 2021 — Jan 2022 [monthly]

Active Not Recruiting PHASE2_PHASE3
Oct 2019 — Jan 2021 [monthly]

Active Not Recruiting PHASE2_PHASE3

Phase: PHASE3 → PHASE2_PHASE3

▶ Show 1 earlier version

Aug 2019 — Oct 2019 [monthly]

Active Not Recruiting PHASE3

First recorded

Mar 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Guangxi Medical University

Data source: Guangxi Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nanning, China